UK Dementia Drug Discovery to Receive £45 Million Boost

Alzheimer’s Research UK has announced a renewed five-year commitment to its flagship Drug Discovery Alliance (DDA), backed by up to £45 million of new investment, in what the charity describes as one of its most significant research pledges to date.

The announcement was made at the organisation’s Annual Research Conference in Manchester by Director of Research Dr Sheona Scales, and will see the Alliance — first established in 2015 — enter its third consecutive five-year term.

The DDA brings together more than 80 specialist scientists across three world-leading university institutes at Cambridge, Oxford and University College London, forming the UK’s largest drug discovery network focused on neurodegeneration.

Over the past decade, the Alliance has explored more than 80 potential drug targets, progressed 15 into animal studies, and established partnerships with 13 industry partners to help advance the most promising candidates towards clinical trials.

Dr Scales said the renewed investment would give “more brilliant ideas the chance to become tomorrow’s treatments,” adding that the Alliance was building “real momentum towards a cure.”

For those working in care homes, where residents living with dementia represent a significant proportion of the population, the progress carries particular relevance. The Alliance’s three institutes each focus on complementary areas of research — from helping brain cells clear faulty proteins, to targeting the brain’s immune system and reducing neurological inflammation.

The renewed Alliance will see the three institutes collaborate more closely, sharing expertise, data and resources, with the stated aim of advancing at least one DDA-developed drug into clinical trials within five years.

The announcement comes as the first treatments capable of slowing Alzheimer’s disease begin to reach patients, marking a significant shift in what has historically been a challenging treatment landscape.